Phaseline

Targets › TACR3

TACR3 (Neuromedin-K receptor): drug programs, companies and trials

3 programs from 2 companies in 11 trials: 6 Phase 2, 3 Phase 3, 2 Phase 1; Oncology, Other, Genitourinary; next expected readout Feb 2027.

Receptor for the tachykinin neuromedin-K (neurokinin B), also able to bind and respond to tachynins substance K/neurokinin A and substance P. The rank order of affinity of this receptor to tachykinins is: neuromedin-K > substance K and substance P. Neuromedin-K binding to its receptor triggers G protein-coupled receptor signaling via activation of G(q) and phosphatidylinositol hydrolysis by phospholipase C.…. (UniProt, P29371)

Open in Phaseline: the race on TACR3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
BayerElinzanetant (BAY3427080)
Neurokinin 1 receptor antagonist; Neurokinin 3 receptor antagonist
TACR1, TACR3Phase 3Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer; Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women; Menopause-related Hot FlashesFeb 2027
Astellasfezolinetant
Neurokinin 3 receptor antagonist
TACR3Phase 3Hot Flashes; Prostate Cancer; Prostate CA; Vasomotor Symptoms …Apr 2027
AstellasFezolinetant
Neurokinin 3 receptor antagonist
TACR3Phase 3Hot FlashesMar 2028

Conditions

Hot Flashes (2) Prostate Cancer (2) Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer (1) Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women (1) Menopause-related Hot Flashes (1) Prostate CA (1) Vasomotor Symptoms (1) Breast Cancer Early Stage Breast Cancer (Stage 1-3) (1) Menopause (1)

Modalities

small molecule (3)

Companies

Astellas (2) Bayer (1)

Related targets

TACR1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.